A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

This study is testing a drug called praliciguat for people with focal segmental glomerulosclerosis (FSGS) — a kidney disease that causes scarring of the kidney's filtering units, leading to significant protein loss in the urine and progressive kidney damage. **You may be eligible if...** - You have significant protein in your urine (urine protein-to-creatinine ratio of 1 or higher) - Your kidney function, while reduced, is not critically impaired (eGFR of at least 25 mL/min/1.73m²) - Your FSGS has been confirmed by kidney biopsy within the past 3 years, or you have a genetic mutation known to cause FSGS - You are already on maximum tolerated doses of standard blood-pressure-protecting kidney medications (ACE inhibitors or ARBs) **You may NOT be eligible if...** - Your kidney biopsy showed a particularly aggressive pattern called "collapsing FSGS" - You have sickle cell disease - Your blood sugar control is poor (HbA1c above 8% or high non-fasting glucose) - Your blood pressure is severely uncontrolled (140/100 mmHg or higher despite medication) Talk to your doctor to see if this trial is right for you.